The MediBeacon Transdermal GFR System (TGFR) is engineered to allow detection of the change in levels of a fluorescent GFR tracer agent over time via a sensor placed on the patient’s skin. The TGFR Monitor displays this information in the form of a transdermal GFR (tGFR) which may be useful in the understanding of kidney function.
The Transdermal GFR System (TGFR) has been designed to report a tGFR across the full range of human skin colors as quantified by the Fitzpatrick Skin Phototype (FSP).
According to the CDC 2023 Chronic Kidney Disease (CKD) Factsheet, more than 1 in 7 adults in the US are estimated to have CKD, and approximately 1 in 5 adults with high blood pressure and 1 in 3 adults with diabetes have CKD. The MediBeacon Transdermal GFR System (TGFR) received FDA approval to assess kidney function.